Pantec Biosolutions Closes CHF 20 Million Financing

21-Jul-2010 - Pantec Biosolutions AG announced the closing of a CHF 20 million investment achieved by two financing rounds. The StemCell Holding AG, an Austrian investment company in the life sciences sector, acted as lead investor. No further terms were disclosed. The investment strengthens Pantec’s ...

Pantec Biosolutions reports successful Phase I for delivery of FSH

First time a protein this large has ever been successfully delivered transdermally

26-Feb-2010 - Pantec Biosolutions AG announced that it has achieved excellent results in a Phase I clinical trial of a FSH (follicle stimulating hormone) patch used in conjunction with the company’s novel P.L.E.A.S.E.® (Painless Laser Epidermal System) technology. Although smaller peptides and some proteins ...

Pantec Biosolutions Granted European Patent for P.L.E.A.S.E

28-Sep-2009 - Pantec Biosolutions AG announced that it has been granted European Patent No. EP1874213, entitled ‘LASER MICROPORATOR’ by the European Patent Office. The patent, which was granted in September, covers the technology used in the company’s lead product P.L.E.A.S.E.® (Painless Laser Epidermal ...

Pantec Biosolutions receives ISO 13485 certification

29-Sep-2008 - Pantec Biosolutions AG announced that it has successfully established a Quality Management System (QMS) in accordance with ISO 13485:2003 standards for medical devices. In order to achieve ISO standards, Pantec Biosolutions implemented a QMS for its operations to ensure consistent quality of the ...

Pantec Biosolutions appoints new Board members

New appointments are set to enhance future business and finance strategies

19-May-2008 - Pantec Biosolutions AG, a privately-owned company developing technologies for transdermal drug delivery, announced the appointment of Burkhard Feurstein and Michael Armbruester to the Board following their election at the annual shareholders meeting held on April 24, 2008. Mr Feurstein is ...